Amy Huang – General Manager, OBI Pharma, Taiwan
In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad Simolenin, as the company also expands its R&D focus to the antibody field.
At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on 4th June 2016, OBI Pharma presented the results of a Phase II/III trial of the investigational immunotherapy Adagloxad Simolenin in patients with metastatic breast cancer. Although the study did not meet its originally designed primary endpoint, it did show interesting efficacy for some specific patients. As general manager of OBI, what makes you believe these results are promising?
Although the study did not meet the primary efficacy endpoint of progression-free survival, Adagloxad Simolenin is an extremely innovative product and proudly stands as a frontrunner in immunology. As a matter of fact, the KOLs and experts that we met at the annual meetings of ASCO and the European Society for Medical Oncology (ESMO) encouraged us to move forward on the development of our product and start global trials, because they believed that this vaccine can really be a benefit to cancer patients and our vaccine is well-tolerated with no major safety concerns.